Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KIT exon11 KIT exon17 |
Therapy | PLX9486 |
Indication/Tumor Type | gastrointestinal stromal tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT exon11 KIT exon17 | gastrointestinal stromal tumor | predicted - sensitive | PLX9486 | Phase I | Actionable | In a Phase I trial, PLX9486 treatment resulted in partial response with 33% decrease of tumor size after 4 cycles of therapy in a patient with gastrointestinal stromal tumor harboring a primary KIT exon 11 mutation and a secondary KIT exon 17 mutation, who progressed on prior Gleevec (imatinib mesylate) and Sutent (sunitinib) therapies (CTOS Annual Meeting, Nov 2017, abstract # 2771952). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
A PHASE 1 PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) STUDY OF PLX9486, ANOVEL KIT INHIBITOR WITH POTENT ACTIVITY AGAINST EXON 17/18 ACTIVATION LOOP MUTATIONS IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST) | Full reference... |